All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Bristol Myers Squibb, Evinova partner on AI clinical development platform to improve efficiency and cut costs
Research collaboration, AI/ML, drug discovery, R&D, global - Read more

Fresenius Kabi, Phlow collaborate on end-to-end US epinephrine injection manufacturing to address chronic shortages
Manufacturing agreement, small molecule, supply chain resilience, API production - Read more

Takeda, Iambic partner on AI drug discovery for oncology and inflammatory diseases, $1.7B+ milestones
Research collaboration, AI/ML, small molecule, oncology, milestone payments - Read more

Ethris, German Center for Infection Research collaborate on next-generation mRNA vaccine development
Research collaboration, infectious disease, mRNA vaccine, drug discovery - Read more

Memo Therapeutics, CSL collaborate on recombinant polyclonal IgG technology, up to CHF 265M ($328M) milestones
Research collaboration, rare disease, antibody, milestone payments - Read more

Basilea Pharmaceutica receives $5M milestone payment from Pfizer for strong Cresemba sales in Asia Pacific
Small molecule, infectious disease, financial, milestone payment - Read more

THE GOOD
Clinical Trials

Breye Therapeutics reports positive Ph1b results for danegaptide targeting non-proliferative diabetic retinopathy with macular edema
Small molecule, metabolic, diabetic retinopathy, vascular stabilization, oral therapy - Read more

Chugai Pharmaceutical's NXT007 shows favorable tolerability in Ph1/2 trial for hemophilia A patients switching from emicizumab
Antibody, hematological, bispecific antibody, hemophilia A, factor VIII - Read more

Biofrontera's Ameluz (aminolevulinic acid) photodynamic therapy meets Ph3 primary endpoint for actinic keratoses treatment
Photodynamic therapy, dermatological, actinic keratoses, aminolevulinic acid, field-directed therapy - Read more

PRESENTED BY FACET LIFE SCIENCES
Facet Life Sciences Makes Emerging Biotech Approvable

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

✅ More Good News ✅

THE GOOD
Company Launches

Vesalic Limited emerges from stealth with discovery of non-CNS driver for motor neuron diseases including ALS
Neurological, strategic, operational, discovery - Read more

THE GOOD
Fundraises

Aerska raises $39M Series A, brain shuttle technology for RNA medicines
RNA therapeutics, neurological, brain shuttle technology, RNAi, Alzheimer disease, preclinical - Read more

Galux raises $29M Series B, AI-driven protein design for drug discovery
AI/ML platform, protein design, antibody, drug discovery, platform technology, preclinical - Read more

QuantX Biosciences raises $85M Series B for computational drug discovery platform
Computational drug discovery, small molecule, immunology, platform technology - Read more

THE GOOD
Mergers & Acquisitions

Eli Lilly to acquire Orna Therapeutics for $2.4B for their in vivo CAR T tech, targeting autoimmunity
CAR-T, autoimmune, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA rejects Regenxbio's RGX-121 gene therapy for Hunter syndrome over trial design concerns
Gene therapy, metabolic, Hunter syndrome, heparan sulfate biomarker - Read more

THE BAD
Lawsuits

Novo Nordisk sues Hims & Hers over compounded semaglutide patent infringement, seeking hundreds of millions in damages
Small molecule, metabolic, strategic, competitive - Read more

THE UGLY
Regulatory

FDA issues Class I recall on J&J Medtech Cerepak coils after death and serious injuries
Medical device, neurological, regulatory, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here